Fucoxanthin attenuates LPS-induced acute lung injury via inhibition of the TLR4/MyD88 signaling axis

Aging (Albany NY). 2020 Dec 11;13(2):2655-2667. doi: 10.18632/aging.202309. Epub 2020 Dec 11.

Abstract

Acute lung injury (ALI) is a critical clinical condition with a high mortality rate. It is believed that the inflammatory storm is a critical contributor to the occurrence of ALI. Fucoxanthin is a natural extract from marine seaweed with remarkable biological properties, including antioxidant, anti-tumor, and anti-obesity. However, the anti-inflammatory activity of Fucoxanthin has not been extensively studied. The current study aimed to elucidate the effects and the molecular mechanism of Fucoxanthin on lipopolysaccharide-induced acute lung injury. In this study, Fucoxanthin efficiently reduced the mRNA expression of pro-inflammatory factors, including IL-10, IL-6, iNOS, and Cox-2, and down-regulated the NF-κB signaling pathway in Raw264.7 macrophages. Furthermore, based on the network pharmacological analysis, our results showed that anti-inflammation signaling pathways were screened as fundamental action mechanisms of Fucoxanthin on ALI. Fucoxanthin also significantly ameliorated the inflammatory responses in LPS-induced ALI mice. Interestingly, our results revealed that Fucoxanthin prevented the expression of TLR4/MyD88 in Raw264.7 macrophages. We further validated Fucoxanthin binds to the TLR4 pocket using molecular docking simulations. Altogether, these results suggest that Fucoxanthin suppresses the TLR4/MyD88 signaling axis by targeting TLR4, which inhibits LPS-induced ALI, and fucoxanthin inhibition may provide a novel strategy for controlling the initiation and progression of ALI.

Keywords: LPS; MyD88; NF-κB; TLR4; acute lung injury; fucoxanthin.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Lung Injury / chemically induced*
  • Acute Lung Injury / drug therapy*
  • Acute Lung Injury / pathology
  • Animals
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
  • Bronchoalveolar Lavage Fluid / chemistry
  • Cyclooxygenase 2 Inhibitors / therapeutic use
  • Cytokines / antagonists & inhibitors
  • Lipopolysaccharides*
  • Mice
  • Molecular Docking Simulation
  • Myeloid Differentiation Factor 88 / antagonists & inhibitors*
  • NF-kappa B / drug effects
  • Nitric Oxide Synthase Type II / antagonists & inhibitors
  • RAW 264.7 Cells
  • Signal Transduction / drug effects*
  • Toll-Like Receptor 4 / antagonists & inhibitors*
  • Xanthophylls / therapeutic use*

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Cyclooxygenase 2 Inhibitors
  • Cytokines
  • Lipopolysaccharides
  • Myd88 protein, mouse
  • Myeloid Differentiation Factor 88
  • NF-kappa B
  • Tlr4 protein, mouse
  • Toll-Like Receptor 4
  • Xanthophylls
  • fucoxanthin
  • Nitric Oxide Synthase Type II
  • Nos2 protein, mouse